TCGA-50-8459, TCGA-50-8459SENT_1,"$ o ( #o Collection Date : _ I","{$,o,(,#o,Collection,Date,:,_,I}","{$,o,(,#o,Collection,Date,:,_,I}","{$,NN,CD,NN,NNP,NNP,:,CD,PRP}","{0,1,1,1,6,1,0,6,8}","{}"
TCGA-50-8459, TCGA-50-8459SENT_2,"Summary Statement","{Summary,Statement}","{Summary,Statement}","{NNP,NNP}","{2,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_3,"The right lower lobectomy reveals a 7.5 cm , moderately differentiated rnucinous adenocarcinoma with angioiymphatic and visceral pleural invasion with no involvement of N1 or N2 lymph nodes and free margins .","{The,right,lower,lobectomy,reveals,a,7.5,cm,"","",moderately,differentiated,rnucinous,adenocarcinoma,with,angioiymphatic,and,visceral,pleural,invasion,with,no,involvement,of,N1,or,N2,lymph,nodes,and,free,margins,.}","{the,right,lower,lobectomy,reveal,a,7.5,cm,"","",moderately,differentiate,rnucinous,adenocarcinoma,with,angioiymphatic,and,visceral,pleural,invasion,with,no,involvement,of,n1,or,n2,lymph,node,and,free,margin,.}","{DT,JJ,JJR,NN,VBZ,DT,CD,NN,"","",RB,VBN,JJ,NN,IN,NN,CC,JJ,JJ,NN,IN,DT,NN,IN,NN,CC,NN,NN,NNS,CC,JJ,NNS,.}","{4,4,2,5,0,8,8,5,0,11,8,13,11,0,11,0,19,19,11,0,22,11,0,28,0,28,28,22,0,31,28,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_4,"Pathologlc stage : T3 No ;","{Pathologlc,stage,:,T3,No,;}","{pathologlc,stage,:,t3,no,;}","{NN,NN,:,NN,DT,:}","{2,0,0,2,4,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_5,"PART 1 : BONE , RIGHT SIXTH RIB , PARTIAL RESECTION ?","{PART,1,:,BONE,"","",RIGHT,SIXTH,RIB,"","",PARTIAL,RESECTION,?}","{part,1,:,bone,"","",RIGHT,SIXTH,rib,"","",partial,resection,?}","{NN,CD,:,NN,"","",NNP,NNP,NN,"","",JJ,NN,NN}","{0,1,0,1,0,8,8,4,0,12,12,4}","{}"
TCGA-50-8459, TCGA-50-8459SENT_6,"SPECIMEN UNDERGOING DECALCIFICATION .","{SPECIMEN,UNDERGOING,DECALCIFICATION,.}","{specimen,undergo,decalcification,.}","{NN,VBG,NN,.}","{0,1,2,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_7,"ADDENDUM REPORT TO FOLLOW .","{ADDENDUM,REPORT,TO,FOLLOW,.}","{ADDENDUM,REPORT,to,follow,.}","{NNP,NNP,TO,VB,.}","{2,4,4,0,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_8,"PART 2 : LYMPH NODE , LEVEL 9 LYMPH NODE NEAR RIGHT INFERIOR LIGAMENT , BIOPSY ? SOLITARY LYMPH NODE WITH REACTIVE CHANGE .","{PART,2,:,LYMPH,NODE,"","",LEVEL,9,LYMPH,NODE,NEAR,RIGHT,INFERIOR,LIGAMENT,"","",BIOPSY,?,SOLITARY,LYMPH,NODE,WITH,REACTIVE,CHANGE,.}","{part,2,:,LYMPH,NODE,"","",LEVEL,9,LYMPH,NODE,near,RIGHT,INFERIOR,LIGAMENT,"","",BIOPSY,?,SOLITARY,LYMPH,NODE,with,REACTIVE,CHANGE,.}","{NN,CD,:,NNP,NNP,"","",NNP,CD,NNP,NNP,IN,NNP,NNP,NNP,"","",NNP,CD,NNP,NNP,NNP,IN,NNP,NNP,.}","{0,1,0,5,1,0,10,10,10,5,0,14,14,10,0,20,20,20,20,14,0,23,10,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_9,"NO EVIDENCE OF MALIGNANCY .","{NO,EVIDENCE,OF,MALIGNANCY,.}","{no,evidence,of,malignancy,.}","{NN,NN,IN,NN,.}","{2,0,0,2,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_10,"PART 3 : LYMPH NODE , SUBCARINAL PACKET , BIOPSY FOUR","{PART,3,:,LYMPH,NODE,"","",SUBCARINAL,PACKET,"","",BIOPSY,FOUR}","{part,3,:,LYMPH,NODE,"","",SUBCARINAL,PACKET,"","",BIOPSY,four}","{NN,CD,:,NNP,NNP,"","",NNP,NNP,"","",NNP,CD}","{0,1,0,5,1,0,8,5,0,5,10}","{}"
TCGA-50-8459, TCGA-50-8459SENT_11,"FRAGMENTS OF LYMPH NODE WITH REACTIVE CHANGE .","{FRAGMENTS,OF,LYMPH,NODE,WITH,REACTIVE,CHANGE,.}","{fragment,of,LYMPH,NODE,with,REACTIVE,CHANGE,.}","{NNS,IN,NNP,NNP,IN,NNP,NNP,.}","{0,0,4,1,0,7,1,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_12,"NO EVIDENCE OF MALIGNANCY .","{NO,EVIDENCE,OF,MALIGNANCY,.}","{no,evidence,of,malignancy,.}","{NN,NN,IN,NN,.}","{2,0,0,2,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_13,"PART 4 : LYMPH NODE , SUBCARINAL NEAR MAIN BRONCHUS , ' BIOPSY TWO","{PART,4,:,LYMPH,NODE,"","",SUBCARINAL,NEAR,MAIN,BRONCHUS,"","",',BIOPSY,TWO}","{part,4,:,LYMPH,NODE,"","",SUBCARINAL,near,MAIN,BRONCHUS,"","",',biopsy,two}","{NN,CD,:,NNP,NNP,"","",NNP,IN,NNP,NNP,"","",'',NN,CD}","{0,1,0,5,1,0,5,0,10,7,0,0,10,13}","{}"
TCGA-50-8459, TCGA-50-8459SENT_14,"FRAGMENT OF LYMPH NODE WITH REACTIVE CHANGE INCLUDING ANTHRACOSILICOTIC NODULES WITH NECROSIS .","{FRAGMENT,OF,LYMPH,NODE,WITH,REACTIVE,CHANGE,INCLUDING,ANTHRACOSILICOTIC,NODULES,WITH,NECROSIS,.}","{fragment,of,LYMPH,NODE,with,REACTIVE,CHANGE,INCLUDING,ANTHRACOSILICOTIC,NODULES,with,NECROSIS,.}","{NN,IN,NNP,NNP,IN,NNP,NNP,NNP,NNP,NNPS,IN,NNP,.}","{0,0,4,1,0,10,10,10,10,1,0,1,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_15,"NO EVIDENCE OF MALIGNANCY .","{NO,EVIDENCE,OF,MALIGNANCY,.}","{no,evidence,of,malignancy,.}","{NN,NN,IN,NN,.}","{2,0,0,2,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_16,"PART 5 : LYMPH NODE , LEVEL 12 "" LYMPH NODE NEAR FISSURE ? , BIOPSY - TWO","{PART,5,:,LYMPH,NODE,"","",LEVEL,12,""\"""",LYMPH,NODE,NEAR,FISSURE,?,"","",BIOPSY,-,TWO}","{part,5,:,LYMPH,NODE,"","",LEVEL,12,""\"""",LYMPH,NODE,near,fissure,?,"","",biopsy,-,two}","{NN,CD,:,NNP,NNP,"","",NNP,CD,``,NNP,NNP,IN,NN,CD,"","",NN,:,CD}","{0,1,0,5,1,0,5,7,11,11,7,0,11,13,0,13,0,11}","{}"
TCGA-50-8459, TCGA-50-8459SENT_17,"FRAGMENTS OF LYMPH NODE WITH REACTIVE CHANGE .","{FRAGMENTS,OF,LYMPH,NODE,WITH,REACTIVE,CHANGE,.}","{fragment,of,LYMPH,NODE,with,REACTIVE,CHANGE,.}","{NNS,IN,NNP,NNP,IN,NNP,NNP,.}","{0,0,4,1,0,7,1,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_18,"NO EVIDENCE OF MALIGNANCY .","{NO,EVIDENCE,OF,MALIGNANCY,.}","{no,evidence,of,malignancy,.}","{NN,NN,IN,NN,.}","{2,0,0,2,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_19,"PART 6 : LYMPH NODE , ? LYMPH NODE NEAR MIDDLE LOBE ARTERY ? , BIOPSY TWO","{PART,6,:,LYMPH,NODE,"","",?,LYMPH,NODE,NEAR,MIDDLE,LOBE,ARTERY,?,"","",BIOPSY,TWO}","{part,6,:,LYMPH,NODE,"","",?,LYMPH,NODE,near,MIDDLE,LOBE,artery,?,"","",biopsy,two}","{NN,CD,:,NNP,NNP,"","",CD,NNP,NNP,IN,NNP,NNP,NN,NN,"","",NN,CD}","{0,1,0,5,1,0,9,9,5,0,14,14,14,9,0,14,16}","{}"
TCGA-50-8459, TCGA-50-8459SENT_20,"FRAGMENTS OF LYMPH NODE WITH REACTIVE CHANGE .","{FRAGMENTS,OF,LYMPH,NODE,WITH,REACTIVE,CHANGE,.}","{fragment,of,LYMPH,NODE,with,REACTIVE,CHANGE,.}","{NNS,IN,NNP,NNP,IN,NNP,NNP,.}","{0,0,4,1,0,7,1,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_21,"NO EVIDENCE OF MALIGNANCY .","{NO,EVIDENCE,OF,MALIGNANCY,.}","{no,evidence,of,malignancy,.}","{NN,NN,IN,NN,.}","{2,0,0,2,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_22,"PART 7 : LYMPH NODE , ? LYMPH NODE NEAR FISSURE ? , BIOPSY ?","{PART,7,:,LYMPH,NODE,"","",?,LYMPH,NODE,NEAR,FISSURE,?,"","",BIOPSY,?}","{part,7,:,LYMPH,NODE,"","",?,lymph,node,near,fissure,?,"","",biopsy,?}","{NN,CD,:,NNP,NNP,"","",CD,NN,NN,IN,NN,CD,"","",NN,CD}","{0,1,0,5,1,0,9,9,5,0,9,11,0,5,14}","{}"
TCGA-50-8459, TCGA-50-8459SENT_23,"FIVE FRAGMENTS OF LYMPH NODE WITH REACTIVE CHANGE .","{FIVE,FRAGMENTS,OF,LYMPH,NODE,WITH,REACTIVE,CHANGE,.}","{five,fragment,of,LYMPH,NODE,with,REACTIVE,CHANGE,.}","{CD,NNS,IN,NNP,NNP,IN,NNP,NNP,.}","{2,0,0,5,2,0,8,2,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_24,"NO EVIDENCE OF MALIGNANCY .","{NO,EVIDENCE,OF,MALIGNANCY,.}","{no,evidence,of,malignancy,.}","{NN,NN,IN,NN,.}","{2,0,0,2,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_25,"PART 8 : LYMPH NODE , ? LYMPH NODE NEAR MIDDLE LOBE BRONCI'IUS ? , BIOPSY -","{PART,8,:,LYMPH,NODE,"","",?,LYMPH,NODE,NEAR,MIDDLE,LOBE,BRONCI'IUS,?,"","",BIOPSY,-}","{part,8,:,LYMPH,NODE,"","",?,lymph,node,near,middle,lobe,bronci'ius,?,"","",biopsy,-}","{NN,CD,:,NNP,NNP,"","",CD,NN,NN,IN,JJ,NN,NN,NN,"","",NN,:}","{0,1,0,5,1,0,9,9,1,0,14,14,14,9,0,1,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_26,"TWO FRAGMENTS OF LYMPH NODE WITH REACTIVE CHANGE .","{TWO,FRAGMENTS,OF,LYMPH,NODE,WITH,REACTIVE,CHANGE,.}","{two,fragment,of,LYMPH,NODE,with,REACTIVE,CHANGE,.}","{CD,NNS,IN,NNP,NNP,IN,NNP,NNP,.}","{2,0,0,5,2,0,8,2,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_27,"NO EVIDENCE OF MALIGNANCY .","{NO,EVIDENCE,OF,MALIGNANCY,.}","{no,evidence,of,malignancy,.}","{NN,NN,IN,NN,.}","{2,0,0,2,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_28,"PART 9 : LYMPH NODE , "" LYMPH NODE NEAR MIDDLE LOBE VEIN ? , BIOPSY ?","{PART,9,:,LYMPH,NODE,"","",""\"""",LYMPH,NODE,NEAR,MIDDLE,LOBE,VEIN,?,"","",BIOPSY,?}","{part,9,:,LYMPH,NODE,"","",""\"""",LYMPH,NODE,near,MIDDLE,LOBE,VEIN,?,"","",biopsy,?}","{NN,CD,:,NNP,NNP,"","",``,NNP,NNP,IN,NNP,NNP,NNP,NN,"","",NN,CD}","{0,1,0,5,1,0,9,9,5,0,14,14,14,9,0,9,16}","{}"
TCGA-50-8459, TCGA-50-8459SENT_29,"THREE FRAGMENTS OF LYMPH NODE WITH REACTIVE CHANGE .","{THREE,FRAGMENTS,OF,LYMPH,NODE,WITH,REACTIVE,CHANGE,.}","{three,fragment,of,LYMPH,NODE,with,REACTIVE,CHANGE,.}","{CD,NNS,IN,NNP,NNP,IN,NNP,NNP,.}","{2,0,0,5,2,0,8,2,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_30,"NO EVIDENCE OF MALIGNANCY .","{NO,EVIDENCE,OF,MALIGNANCY,.}","{no,evidence,of,malignancy,.}","{NN,NN,IN,NN,.}","{2,0,0,2,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_31,"PART 10 : LYMPH NODE , ? LYMPH NODE - NEAR BRONCHUS INTERMEDIUS ? , BIOPSY SOLITARY","{PART,10,:,LYMPH,NODE,"","",?,LYMPH,NODE,-,NEAR,BRONCHUS,INTERMEDIUS,?,"","",BIOPSY,SOLITARY}","{part,10,:,LYMPH,NODE,"","",?,lymph,node,-,near,BRONCHUS,INTERMEDIUS,?,"","",BIOPSY,SOLITARY}","{NN,CD,:,NNP,NNP,"","",CD,NN,NN,:,IN,NNP,NNP,CD,"","",NNP,NNP}","{0,1,0,5,1,0,8,5,1,0,9,13,11,13,0,17,13}","{}"
TCGA-50-8459, TCGA-50-8459SENT_32,"LYMPH NODE WITH REACTIVE CHANGE .","{LYMPH,NODE,WITH,REACTIVE,CHANGE,.}","{lymph,node,with,reactive,change,.}","{NN,NN,IN,JJ,NN,.}","{2,3,0,5,3,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_33,"NO EVIDENCE OF MALIGNANCY .","{NO,EVIDENCE,OF,MALIGNANCY,.}","{no,evidence,of,malignancy,.}","{NN,NN,IN,NN,.}","{2,0,0,2,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_34,"PART 11 : LYMPH NODE , ? LEVEL 11 LYMPH NODE NEAR VASTUS OF MIDDLE LOBE VEIN "" , BIOPSY TWO","{PART,11,:,LYMPH,NODE,"","",?,LEVEL,11,LYMPH,NODE,NEAR,VASTUS,OF,MIDDLE,LOBE,VEIN,""\"""","","",BIOPSY,TWO}","{part,11,:,LYMPH,NODE,"","",?,level,11,LYMPH,NODE,near,VASTUS,of,MIDDLE,LOBE,VEIN,""\"""","","",biopsy,two}","{NN,CD,:,NNP,NNP,"","",CD,NN,CD,NNP,NNP,IN,NNPS,IN,NNP,NNP,NNP,``,"","",NN,CD}","{0,1,0,5,1,0,8,5,11,11,8,0,11,0,13,13,16,13,0,5,20}","{}"
TCGA-50-8459, TCGA-50-8459SENT_35,"FRAGNIENTS OF LYMPH NODE WITH REACTIVE CHANGE .","{FRAGNIENTS,OF,LYMPH,NODE,WITH,REACTIVE,CHANGE,.}","{fragnient,of,LYMPH,NODE,with,REACTIVE,CHANGE,.}","{NNS,IN,NNP,NNP,IN,NNP,NNP,.}","{0,0,4,1,0,7,1,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_36,"NO EVIDENCE OF MALIGNANCY .","{NO,EVIDENCE,OF,MALIGNANCY,.}","{no,evidence,of,malignancy,.}","{NN,NN,IN,NN,.}","{2,0,0,2,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_37,"PART 12 : SOFT TISSUE , "" TISSUE NEAR FISSURE "" .","{PART,12,:,SOFT,TISSUE,"","",""\"""",TISSUE,NEAR,FISSURE,""\"""",.}","{part,12,:,soft,tissue,"","",""\"""",tissue,near,fissure,""\"""",.}","{NN,CD,:,JJ,NN,"","",``,VB,IN,NN,'',.}","{0,1,0,5,1,0,8,1,0,8,10,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_38,"BIOPSY ? FRAGMENTS OF BENIGN FIBROADIPOSE TISSUE .","{BIOPSY,?,FRAGMENTS,OF,BENIGN,FIBROADIPOSE,TISSUE,.}","{biopsy,?,fragment,of,benign,fibroadipose,tissue,.}","{NN,CD,NNS,IN,JJ,JJ,NN,.}","{0,3,1,0,7,7,3,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_39,"PART 13 : LYMPH NODE .","{PART,13,:,LYMPH,NODE,.}","{part,13,:,LYMPH,NODE,.}","{NN,CD,:,NNP,NNP,.}","{0,1,0,5,1,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_40,"? FISSURE LYMPH NODE NEAR SUPERIOR SEGMENT BRONCHUS "" .","{?,FISSURE,LYMPH,NODE,NEAR,SUPERIOR,SEGMENT,BRONCHUS,""\"""",.}","{?,fissure,lymph,node,near,SUPERIOR,SEGMENT,bronchus,""\"""",.}","{NN,NN,NN,NN,IN,NNP,NNP,NNS,``,.}","{4,4,4,9,0,8,8,4,0,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_41,"BIOPSY ?","{BIOPSY,?}","{biopsy,?}","{NN,SYM}","{0,1}","{}"
TCGA-50-8459, TCGA-50-8459SENT_42,"A. TWO FRAGMENTS OF LYMPH NODE WITH REACTIVE CHANGE WITH FOCAL GRANULOMATOUS","{A.,TWO,FRAGMENTS,OF,LYMPH,NODE,WITH,REACTIVE,CHANGE,WITH,FOCAL,GRANULOMATOUS}","{a.,two,fragment,of,LYMPH,NODE,with,REACTIVE,CHANGE,with,focal,granulomatous}","{NN,CD,NNS,IN,NNP,NNP,IN,NNP,NNP,IN,JJ,NN}","{0,3,1,0,6,3,0,9,6,0,12,6}","{}"
TCGA-50-8459, TCGA-50-8459SENT_43,"REACTION To FOREIGN MATERIAL .","{REACTION,To,FOREIGN,MATERIAL,.}","{reaction,to,foreign,material,.}","{NN,TO,JJ,NN,.}","{0,0,4,1,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_44,"enocorr AND ACID FAST STAINS FOR MICROORGANISMS ARE NEGATIVE .","{enocorr,AND,ACID,FAST,STAINS,FOR,MICROORGANISMS,ARE,NEGATIVE,.}","{enocorr,and,acid,fast,stain,for,microorganism,be,negative,.}","{NN,CC,NN,NN,NNS,IN,NNS,VBP,NN,.}","{9,0,5,5,9,0,9,9,0,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_45,"CORRELATION WITH CULTURE RESULTS SUGGESTED .","{CORRELATION,WITH,CULTURE,RESULTS,SUGGESTED,.}","{correlation,with,culture,result,suggest,.}","{NN,IN,NN,NNS,VBD,.}","{5,0,4,1,0,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_46,"e. No EVIDENCE or MALIGNANCY .","{e.,No,EVIDENCE,or,MALIGNANCY,.}","{e.,No,evidence,or,malignancy,.}","{NNP,NNP,NN,CC,NN,.}","{2,0,2,0,2,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_47,"PART 14 : LYMPH NODE , ? LEVEL 11 LYMPH NODE NEAR BASILAR BRONCHUS ? .","{PART,14,:,LYMPH,NODE,"","",?,LEVEL,11,LYMPH,NODE,NEAR,BASILAR,BRONCHUS,?,.}","{part,14,:,LYMPH,NODE,"","",?,level,11,LYMPH,NODE,near,BASILAR,BRONCHUS,?,.}","{NN,CD,:,NNP,NNP,"","",CD,NN,CD,NNP,NNP,IN,NNP,NNP,CD,.}","{0,1,0,5,1,0,8,1,8,11,1,0,14,11,14,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_48,"BIOPSY THREE","{BIOPSY,THREE}","{biopsy,three}","{NN,CD}","{0,1}","{}"
TCGA-50-8459, TCGA-50-8459SENT_49,"FRAGMENTS OF LYMPH NODE WITH REACTIVE CHANGE .","{FRAGMENTS,OF,LYMPH,NODE,WITH,REACTIVE,CHANGE,.}","{fragment,of,LYMPH,NODE,with,REACTIVE,CHANGE,.}","{NNS,IN,NNP,NNP,IN,NNP,NNP,.}","{0,0,4,1,0,7,1,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_50,"NO EVIDENCE OF MALIGNANCY .","{NO,EVIDENCE,OF,MALIGNANCY,.}","{no,evidence,of,malignancy,.}","{NN,NN,IN,NN,.}","{2,0,0,2,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_51,"PART 1 5 : LUNG , RIGHT LOWER LOBE , LOBECTOMY A.","{PART,1,5,:,LUNG,"","",RIGHT,LOWER,LOBE,"","",LOBECTOMY,A.}","{part,1,5,:,lung,"","",RIGHT,LOWER,LOBE,"","",LOBECTOMY,a.}","{NN,CD,CD,:,NN,"","",NNP,NNP,NNP,"","",NNP,NN}","{0,3,1,0,1,0,9,9,5,0,12,5}","{}"
TCGA-50-8459, TCGA-50-8459SENT_52,"INVASIVE MODERATELY DIFFERENTIATED MUCINOUS ADENOCARCINOMA , DIAMETER 7.5 CM , WITH","{INVASIVE,MODERATELY,DIFFERENTIATED,MUCINOUS,ADENOCARCINOMA,"","",DIAMETER,7.5,CM,"","",WITH}","{invasive,moderately,differentiate,mucinous,adenocarcinoma,"","",diameter,7.5,cm,"","",with}","{JJ,RB,VBN,JJ,NN,"","",NN,CD,NN,"","",IN}","{0,3,1,5,3,0,9,9,5,0,3}","{}"
TCGA-50-8459, TCGA-50-8459SENT_53,"VISCERAL PLEURAL AND ANGIOLYMPI-IATIC INVASION .","{VISCERAL,PLEURAL,AND,ANGIOLYMPI-IATIC,INVASION,.}","{visceral,pleural,and,angiolympi-iatic,invasion,.}","{JJ,NN,CC,NN,NN,.}","{2,0,0,5,2,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_54,"ALL MARGINS FREE .","{ALL,MARGINS,FREE,.}","{all,margin,free,.}","{NN,NNS,VBP,.}","{2,3,0,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_55,"MILD HOST LYMPHOCYTIC RESPONSE .","{MILD,HOST,LYMPHOCYTIC,RESPONSE,.}","{mild,host,lymphocytic,response,.}","{JJ,NN,NN,NN,.}","{2,0,4,2,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_56,"PATHOLOGIC STAGE : T3 No. .","{PATHOLOGIC,STAGE,:,T3,No.,.}","{PATHOLOGIC,STAGE,:,t3,no.,.}","{NNP,NNP,:,NN,NN,.}","{2,0,0,5,2,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_57,"B. TEN LOBAR LYMPH NODES WITH REACTIVE CHANGE .","{B.,TEN,LOBAR,LYMPH,NODES,WITH,REACTIVE,CHANGE,.}","{B.,TEN,LOBAR,LYMPH,node,with,reactive,change,.}","{NNP,NNP,NNP,NNP,VBZ,IN,JJ,NN,.}","{4,4,4,5,0,0,8,5,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_58,"NO EVIDENCE OF MALIGNANCY .","{NO,EVIDENCE,OF,MALIGNANCY,.}","{no,evidence,of,malignancy,.}","{NN,NN,IN,NN,.}","{2,0,0,2,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_59,"MILD EMPHYSEMATOUS CHANGE .","{MILD,EMPHYSEMATOUS,CHANGE,.}","{mild,emphysematous,change,.}","{JJ,NNS,VBP,.}","{2,3,0,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_60,"COMMENT : The invasive moderately differentiated mucinous adenocarcinoma shows a variety of architectural patterns with lepidic and papillary patterns predominant .","{COMMENT,:,The,invasive,moderately,differentiated,mucinous,adenocarcinoma,shows,a,variety,of,architectural,patterns,with,lepidic,and,papillary,patterns,predominant,.}","{COMMENT,:,the,invasive,moderately,differentiate,mucinous,adenocarcinoma,show,a,variety,of,architectural,pattern,with,lepidic,and,papillary,pattern,predominant,.}","{NNP,:,DT,JJ,RB,VBN,JJ,NN,VBZ,DT,NN,IN,JJ,NNS,IN,NN,CC,NN,NNS,JJ,.}","{0,0,8,8,4,4,6,9,1,11,20,0,14,11,0,19,0,19,14,9,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_61,"although the areas of invasion show the predominance of acinar growth .","{although,the,areas,of,invasion,show,the,predominance,of,acinar,growth,.}","{although,the,area,of,invasion,show,the,predominance,of,acinar,growth,.}","{IN,DT,NNS,IN,NN,VBP,DT,NN,IN,JJ,NN,.}","{6,3,6,0,3,0,8,6,0,11,8,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_62,"Multiple small satellite lesions are seen within 1 cm of the main tumor mass and representative sectioning of the remainder of the lobe fails to show gross satellite nodules .","{Multiple,small,satellite,lesions,are,seen,within,1,cm,of,the,main,tumor,mass,and,representative,sectioning,of,the,remainder,of,the,lobe,fails,to,show,gross,satellite,nodules,.}","{multiple,small,satellite,lesion,be,see,within,1,cm,of,the,main,tumor,mass,and,representative,sectioning,of,the,remainder,of,the,lobe,fail,to,show,gross,satellite,nodule,.}","{JJ,JJ,NN,NNS,VBP,VBN,IN,CD,NN,IN,DT,JJ,NN,NN,CC,JJ,NN,IN,DT,NN,IN,DT,NN,VBZ,TO,VB,JJ,NN,NNS,.}","{4,4,4,6,6,0,0,9,6,0,14,14,14,9,0,17,24,0,20,17,0,23,20,6,26,24,29,29,26,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_63,"PAS , PAS-D and mucicarmine stains are strongly positive in the neoplastic cells .","{PAS,"","",PAS-D,and,mucicarmine,stains,are,strongly,positive,in,the,neoplastic,cells,.}","{pa,"","",pas-d,and,mucicarmine,stain,be,strongly,positive,in,the,neoplastic,cell,.}","{NN,"","",NN,CC,NN,NNS,VBP,RB,JJ,IN,DT,JJ,NNS,.}","{6,0,6,0,6,9,9,9,0,0,13,13,9,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_64,"WG stains show visceral pleural invasion ( D Block ) .","{WG,stains,show,visceral,pleural,invasion,(,D,Block,),.}","{wg,stain,show,visceral,pleural,invasion,(,d,Block,),.}","{NN,NNS,VBP,JJ,JJ,NN,NN,NN,NNP,CD,.}","{2,3,0,7,7,7,3,7,8,9,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_65,"lmmunoperoxidase stains show that the tumor cells are negative for p63 and oytokeratin 516 and fail to express TTF-1 .","{lmmunoperoxidase,stains,show,that,the,tumor,cells,are,negative,for,p63,and,oytokeratin,516,and,fail,to,express,TTF-1,.}","{lmmunoperoxidase,stain,show,that,the,tumor,cell,be,negative,for,p63,and,oytokeratin,516,and,fail,to,express,ttf-1,.}","{NN,NNS,VBP,IN,DT,NN,NNS,VBP,JJ,IN,NN,CC,NN,CD,CC,VBP,TO,VB,NN,.}","{2,3,0,9,7,7,16,9,3,0,9,0,9,9,0,3,18,16,18,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_66,"Grocott and-acid-fast stains are negative .","{Grocott,and-acid-fast,stains,are,negative,.}","{Grocott,and-acid-fast,stain,be,negative,.}","{NNP,JJ,NNS,VBP,JJ,.}","{3,3,5,5,0,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_67,"sections of the part1 "" right sixth rib "" show normal bone and bone marrow with trilineage representation and maturation .","{sections,of,the,part1,""\"""",right,sixth,rib,""\"""",show,normal,bone,and,bone,marrow,with,trilineage,representation,and,maturation,.}","{section,of,the,part1,""\"""",right,sixth,rib,""\"""",show,normal,bone,and,bone,marrow,with,trilineage,representation,and,maturation,.}","{NNS,IN,DT,NN,'',RB,JJ,NN,'',NN,JJ,NN,CC,NN,NN,IN,NN,NN,CC,NN,.}","{10,0,4,1,4,4,8,6,4,0,12,10,0,15,12,0,18,12,0,18,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_68,"No evidence of maiignancy is seen .","{No,evidence,of,maiignancy,is,seen,.}","{no,evidence,of,maiignancy,be,see,.}","{DT,NN,IN,NN,VBZ,VBN,.}","{2,6,0,2,6,0,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_69,"COMPREHENSIVE THERANOSTIC SUMMARY","{COMPREHENSIVE,THERANOSTIC,SUMMARY}","{comprehensive,theranostic,summary}","{JJ,NN,NN}","{3,3,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_70,"IMMUNOHISTOCHEMISTRY ' IN SITU HYBRIDIZATION I FISH ALK rearrangement : NEGATIVE C-MET ampii?catiori : NEGATIVE","{IMMUNOHISTOCHEMISTRY,',IN,SITU,HYBRIDIZATION,I,FISH,ALK,rearrangement,:,NEGATIVE,C-MET,ampii?catiori,:,NEGATIVE}","{immunohistochemistry,',in,SITU,HYBRIDIZATION,I,fish,alk,rearrangement,:,negative,c-met,ampii?catiori,:,negative}","{NN,'',IN,NNP,NNP,NNP,NN,NN,NN,:,JJ,JJ,NNS,:,NN}","{0,0,0,9,9,9,9,9,1,0,13,13,1,0,13}","{}"
TCGA-50-8459, TCGA-50-8459SENT_71,"MOLECULAR ANAT MIC PATHOLOGY EGFR exon 18 mutation : NEGATIVE EGFR exon 19 mutation : NEGATIVE EGFR exon 20 mutation : NEGATIVE EGFR exon 21 mutation : NEGATIVE BRAF exon 15 mutation ( PCRI : NEGATIVE _ I KRAS exon 2 ( codons 12 , 13 } mutation ( PCR ) : POSITIVE ( mutation type .","{MOLECULAR,ANAT,MIC,PATHOLOGY,EGFR,exon,18,mutation,:,NEGATIVE,EGFR,exon,19,mutation,:,NEGATIVE,EGFR,exon,20,mutation,:,NEGATIVE,EGFR,exon,21,mutation,:,NEGATIVE,BRAF,exon,15,mutation,(,PCRI,:,NEGATIVE,_,I,KRAS,exon,2,(,codons,12,"","",13,""}"",mutation,(,PCR,),:,POSITIVE,(,mutation,type,.}","{MOLECULAR,ANAT,MIC,PATHOLOGY,egfr,exon,18,mutation,:,negative,egfr,exon,19,mutation,:,negative,egfr,exon,20,mutation,:,negative,egfr,exon,21,mutation,:,NEGATIVE,BRAF,exon,15,mutation,(,PCRI,:,NEGATIVE,_,I,kra,exon,2,(,codon,12,"","",13,""}"",mutation,(,pcr,),:,positive,(,mutation,type,.}","{NNP,NNP,NNP,NNP,NN,NN,CD,NN,:,JJ,NN,NN,CD,NN,:,JJ,NN,NN,CD,NN,:,JJ,NN,NN,CD,NN,:,NNP,NNP,NN,CD,NN,CD,NNP,:,NNP,CD,PRP,VBP,NN,CD,CD,NNS,CD,"","",CD,NN,NN,CD,NN,NN,:,JJ,NN,NN,NN,.}","{6,6,6,6,6,0,8,6,0,12,12,6,14,12,0,18,18,6,20,18,0,24,24,6,26,24,0,30,30,6,30,34,34,30,0,6,36,39,36,39,42,43,40,40,0,47,40,51,51,51,47,0,56,56,56,39,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_72,"p. G12C ) KRAS exon 3 ( codon 61 ) mutation ( PCR ) : NEGATIVE","{p.,G12C,),KRAS,exon,3,(,codon,61,),mutation,(,PCR,),:,NEGATIVE}","{p.,g12c,),KRAS,exon,3,(,codon,61,),mutation,(,pcr,),:,negative}","{NN,NN,CD,NNP,NN,CD,NN,NN,CD,NN,NN,CD,NN,NN,:,NN}","{2,11,5,5,2,7,11,11,11,11,16,14,14,11,0,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_73,"CASE SYNOPSIS :","{CASE,SYNOPSIS,:}","{case,synopsis,:}","{NN,NNS,:}","{2,0,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_74,"SYNOPTIC DATA - PRIMARY LUNG TUM","{SYNOPTIC,DATA,-,PRIMARY,LUNG,TUM}","{SYNOPTIC,DATA,-,PRIMARY,lung,tum}","{NNP,NNP,:,NNP,NN,NN}","{2,0,0,6,6,2}","{}"
TCGA-50-8459, TCGA-50-8459SENT_75,"PROCEDURE : Lobectorny TUMOR SIZE : Maximum dimension : 7.5 cm","{PROCEDURE,:,Lobectorny,TUMOR,SIZE,:,Maximum,dimension,:,7.5,cm}","{procedure,:,Lobectorny,TUMOR,SIZE,:,Maximum,dimension,:,7.5,cm}","{NN,:,NNP,NNP,NNP,:,NNP,NN,:,CD,NN}","{0,0,5,5,1,0,8,5,0,11,8}","{}"
TCGA-50-8459, TCGA-50-8459SENT_76,"Minor dimension : 7.0 cm","{Minor,dimension,:,7.0,cm}","{minor,dimension,:,7.0,cm}","{JJ,NN,:,CD,NN}","{2,0,0,5,2}","{}"
TCGA-50-8459, TCGA-50-8459SENT_77,"GROSS SATELLITES : Number of gross satellite lesions : o TUMOR TYPE : Invasive adenocarcinoma .","{GROSS,SATELLITES,:,Number,of,gross,satellite,lesions,:,o,TUMOR,TYPE,:,Invasive,adenocarcinoma,.}","{gross,satellite,:,number,of,gross,satellite,lesion,:,o,tumor,type,:,invasive,adenocarcinoma,.}","{JJ,NNS,:,NN,IN,JJ,NN,NNS,:,NN,NN,NN,:,JJ,NN,.}","{2,0,0,2,0,8,8,4,0,12,12,2,0,15,12,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_78,"Dominant Pattern : Mucinous HISTOLOGIC GRADE : G2 .","{Dominant,Pattern,:,Mucinous,HISTOLOGIC,GRADE,:,G2,.}","{dominant,pattern,:,mucinous,histologic,grade,:,g2,.}","{JJ,NN,:,JJ,NN,NN,:,NN,.}","{2,0,0,6,6,2,0,6,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_79,"Moderately differentiated MICROSCOPIC "" SATELLITES "" lMETASTASES : Number of microscopic lesions : o EXTRAPULMONARY EXTENSIONIINVASION OF TUMOR : Visceral pleura ( PL1 ) ANGIOLYMPI-IATIC INVASION : Yes ' TUMOR NECROSIS : < or = to 50 % SURGICAL MARGIN INVOLVEMENT : No SURGICAL MARGIN SITE : Distance of invasive tumor to closest margin : 15 mm , Bronchiai margin INFLAMMATORWDESMOPLASTIC ) REACTION : Mild N1 LYMPH NODES : Number of N1 lymph nodes positive : o","{Moderately,differentiated,MICROSCOPIC,""\"""",SATELLITES,""\"""",lMETASTASES,:,Number,of,microscopic,lesions,:,o,EXTRAPULMONARY,EXTENSIONIINVASION,OF,TUMOR,:,Visceral,pleura,(,PL1,),ANGIOLYMPI-IATIC,INVASION,:,Yes,',TUMOR,NECROSIS,:,<,or,=,to,50,%,SURGICAL,MARGIN,INVOLVEMENT,:,No,SURGICAL,MARGIN,SITE,:,Distance,of,invasive,tumor,to,closest,margin,:,15,mm,"","",Bronchiai,margin,INFLAMMATORWDESMOPLASTIC,),REACTION,:,Mild,N1,LYMPH,NODES,:,Number,of,N1,lymph,nodes,positive,:,o}","{moderately,differentiate,microscopic,""\"""",satellite,""\"""",lmetastase,:,number,of,microscopic,lesion,:,o,extrapulmonary,extensioniinvasion,of,tumor,:,visceral,pleuron,(,pl1,),ANGIOLYMPI-IATIC,INVASION,:,Yes,',tumor,NECROSIS,:,<,or,=,to,50,%,surgical,margin,involvement,:,no,surgical,margin,site,:,Distance,of,invasive,tumor,to,closest,margin,:,15,mm,"","",Bronchiai,margin,inflammatorwdesmoplastic,),reaction,:,mild,n1,lymph,node,:,number,of,n1,lymph,node,positive,:,o}","{RB,VBN,JJ,``,NNS,'',NN,:,NN,IN,JJ,NNS,:,NN,NN,NNS,IN,NN,:,JJ,NN,NN,NN,CD,NNP,NNP,:,NNP,POS,NN,NNP,:,JJR,CC,JJ,TO,CD,NN,JJ,NN,NN,:,DT,JJ,NN,NN,:,NNP,IN,JJ,NN,TO,JJS,NN,:,CD,NN,"","",NNP,NN,NN,CD,NN,:,JJ,NN,NN,VBZ,:,NN,IN,NN,NN,NNS,JJ,:,NN}","{2,0,5,5,2,5,5,0,5,0,12,9,0,16,16,5,0,16,0,22,22,5,26,26,26,22,0,30,0,5,30,0,40,0,33,0,38,35,40,5,40,0,45,45,5,45,0,5,0,51,48,0,54,51,0,57,5,0,61,61,57,63,61,0,67,67,5,67,0,67,0,74,74,70,74,0,2}","{}"
TCGA-50-8459, TCGA-50-8459SENT_80,"Number of N1 lymph nodes examined : 25","{Number,of,N1,lymph,nodes,examined,:,25}","{number,of,n1,lymph,node,examine,:,25}","{NN,IN,NN,NN,NNS,VBN,:,CD}","{0,0,5,5,1,5,0,5}","{}"
TCGA-50-8459, TCGA-50-8459SENT_81,"N2 LYMPH NODES : _ Number of N2 lymph nodes positive : o Number of N2 lymph nodes examined : 7","{N2,LYMPH,NODES,:,_,Number,of,N2,lymph,nodes,positive,:,o,Number,of,N2,lymph,nodes,examined,:,7}","{n2,lymph,node,:,_,number,of,n2,lymph,node,positive,:,o,number,of,n2,lymph,node,examine,:,7}","{NN,NN,VBZ,:,CD,NN,IN,NN,NN,NNS,JJ,:,NN,NN,IN,NN,NN,NNS,VBN,:,CD}","{2,3,0,0,6,3,0,10,10,6,6,0,14,11,0,18,18,14,18,0,18}","{}"
TCGA-50-8459, TCGA-50-8459SENT_82,"UNDERLYING DISEASE ( S ) : Emphysema T STAGE , PATHOLOGIC : pT3 N STAGE .","{UNDERLYING,DISEASE,(,S,),:,Emphysema,T,STAGE,"","",PATHOLOGIC,:,pT3,N,STAGE,.}","{underlie,disease,(,s,),:,Emphysema,t,stage,"","",PATHOLOGIC,:,pt3,n,stage,.}","{VBG,NN,CD,NN,CD,:,NNP,NN,NN,"","",NNP,:,NN,NN,NN,.}","{0,1,2,2,4,0,9,9,2,0,9,0,15,15,2,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_83,"PATHOLOGIC : pNo MSTAGE , PATHOLOGIC : Not applicable ANCILLARY STUDIES : Histochemical stains .","{PATHOLOGIC,:,pNo,MSTAGE,"","",PATHOLOGIC,:,Not,applicable,ANCILLARY,STUDIES,:,Histochemical,stains,.}","{PATHOLOGIC,:,pNo,MSTAGE,"","",PATHOLOGIC,:,not,applicable,ANCILLARY,study,:,histochemical,stain,.}","{NNP,:,NNP,NNP,"","",NNP,:,RB,JJ,NNP,NNS,:,JJ,NNS,.}","{8,0,4,1,0,4,0,0,11,11,8,0,14,11,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_84,"lmmunohistochemical stains .","{lmmunohistochemical,stains,.}","{lmmunohistochemical,stain,.}","{JJ,NNS,.}","{2,0,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_85,"FESH studies , Molecular studies","{FESH,studies,"","",Molecular,studies}","{fesh,study,"","",molecular,study}","{NN,NNS,"","",JJ,NNS}","{2,0,0,5,2}","{}"
TCGA-50-8459, TCGA-50-8459SENT_86,"In Situ Procedure Interpretation Probe : ROS Dual-Color Break-apart Probe 6p22 .1 ? ' Probe Description : The two probes are overlapped by approximate 60kb","{In,Situ,Procedure,Interpretation,Probe,:,ROS,Dual-Color,Break-apart,Probe,6p22,.1,?,',Probe,Description,:,The,two,probes,are,overlapped,by,approximate,60kb}","{in,Situ,Procedure,Interpretation,Probe,:,ro,dual-color,break-apart,Probe,6p22,.1,?,',Probe,description,:,the,two,probe,be,overlap,by,approximate,60kb}","{IN,NNP,NNP,NNP,NNP,:,NN,NN,NN,NNP,CD,CD,NN,'',NNP,NN,:,DT,CD,NNS,VBP,VBN,IN,JJ,JJ}","{0,5,5,5,22,0,9,9,5,16,10,15,15,0,10,9,0,20,20,22,22,0,0,25,22}","{}"
TCGA-50-8459, TCGA-50-8459SENT_87,"R051 FISH STUDIES PERFORMED ON THE ADENOCARCINOMA ARE NEGATIVE FOR TRANSLOCATION .","{R051,FISH,STUDIES,PERFORMED,ON,THE,ADENOCARCINOMA,ARE,NEGATIVE,FOR,TRANSLOCATION,.}","{r051,fish,study,perform,on,the,adenocarcinoma,be,negative,for,translocation,.}","{NN,NN,NNS,VBD,IN,DT,NN,VBP,JJ,IN,NN,.}","{3,3,4,0,9,7,5,9,4,0,9,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_88,"# of cells analyzed : 67 % cells positive for translocation : o ( o % ) ? % cells negative for translocation : 57 ( 100 ? / o )","{#,of,cells,analyzed,:,67,%,cells,positive,for,translocation,:,o,(,o,%,),?,%,cells,negative,for,translocation,:,57,(,100,?,/,o,)}","{#,of,cell,analyze,:,67,%,cell,positive,for,translocation,:,o,(,o,%,),?,%,cell,negative,for,translocation,:,57,(,100,?,/,o,)}","{#,IN,NNS,VBN,:,CD,NN,NNS,JJ,IN,NN,:,NN,CD,NN,NN,CD,CD,NN,NNS,JJ,IN,NN,:,CD,NN,CD,CD,:,NN,CD}","{0,0,1,3,0,8,8,3,8,0,9,0,16,16,16,8,18,19,20,16,20,0,21,0,26,8,28,26,30,28,30}","{}"
TCGA-50-8459, TCGA-50-8459SENT_89,"Results ROS Methodology Description : _ _ ROS translocation detection is as follows : Norrnai cells without the ROS translocation show green and red signals in juxtaposition .","{Results,ROS,Methodology,Description,:,_,_,ROS,translocation,detection,is,as,follows,:,Norrnai,cells,without,the,ROS,translocation,show,green,and,red,signals,in,juxtaposition,.}","{result,ro,methodology,description,:,_,_,ro,translocation,detection,be,as,follow,:,norrnai,cell,without,the,ro,translocation,show,green,and,red,signal,in,juxtaposition,.}","{NNS,NNS,NN,NN,:,CD,CD,NN,NN,NN,VBZ,IN,VBZ,:,JJ,NNS,IN,DT,NN,NN,VBP,JJ,CC,JJ,NNS,IN,NN,.}","{2,11,4,2,0,7,2,10,10,7,0,13,11,0,16,21,0,20,20,16,11,25,0,25,21,0,25,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_90,"Cells with the ROS translocation show one pair of signals ( green and red ) in iuxtaposition and one green and one red signal separated .","{Cells,with,the,ROS,translocation,show,one,pair,of,signals,(,green,and,red,),in,iuxtaposition,and,one,green,and,one,red,signal,separated,.}","{cell,with,the,ro,translocation,show,one,pair,of,signal,(,green,and,red,),in,iuxtaposition,and,one,green,and,one,red,signal,separate,.}","{NNS,IN,DT,NN,NN,VBP,CD,NN,IN,NNS,CD,JJ,CC,JJ,NN,IN,NN,CC,CD,JJ,CC,CD,JJ,NN,VBN,.}","{6,0,5,5,1,0,8,6,0,8,12,6,0,15,12,0,12,0,20,12,0,24,24,25,6,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_91,"ROS FISH analysis was manually performed and quantitatively assessed by analysis of a minimum of 60 cells using the ROS Texas Red ( centromeric ) and the ROS FlTC ( telomeric ) probes .","{ROS,FISH,analysis,was,manually,performed,and,quantitatively,assessed,by,analysis,of,a,minimum,of,60,cells,using,the,ROS,Texas,Red,(,centromeric,),and,the,ROS,FlTC,(,telomeric,),probes,.}","{ro,fish,analysis,be,manually,perform,and,quantitatively,assess,by,analysis,of,a,minimum,of,60,cell,use,the,ro,Texas,Red,(,centromeric,),and,the,ro,fltc,(,telomeric,),probe,.}","{NN,NN,NN,VBD,RB,VBN,CC,RB,VBN,IN,NN,IN,DT,NN,IN,CD,NNS,VBG,DT,NN,NNP,NNP,NN,JJ,NN,CC,DT,NN,NN,CD,JJ,NN,NNS,.}","{3,3,9,6,6,0,0,9,6,0,9,0,14,11,0,17,14,9,23,23,23,23,18,25,23,0,29,29,23,33,33,33,29,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_92,"SPECIAL PROCEDURES : Molecular Anatomic Pathology Procedure Interpretation","{SPECIAL,PROCEDURES,:,Molecular,Anatomic,Pathology,Procedure,Interpretation}","{special,procedure,:,molecular,anatomic,pathology,Procedure,Interpretation}","{JJ,NNS,:,JJ,JJ,NN,NNP,NNP}","{2,0,0,8,8,8,8,2}","{}"
TCGA-50-8459, TCGA-50-8459SENT_93,"MOLEGU LAR ANATOMIC PATHOLOGY TESTING :","{MOLEGU,LAR,ANATOMIC,PATHOLOGY,TESTING,:}","{MOLEGU,LAR,ANATOMIC,PATHOLOGY,TESTING,:}","{NNP,NNP,NNP,NNP,NNP,:}","{5,5,5,5,0,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_94,"Block 15C :","{Block,15C,:}","{Block,15C,:}","{NNP,NNP,:}","{2,0,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_95,"KRAS codon 12 mutation IDENTIFIED ( p. G12C , c. 34G > T ) .","{KRAS,codon,12,mutation,IDENTIFIED,(,p.,G12C,"","",c.,34G,>,T,),.}","{KRAS,codon,12,mutation,identify,(,p.,g12c,"","",c.,34g,>,t,),.}","{NNP,NN,CD,NN,VBN,CD,NN,NN,"","",NN,NN,JJR,NN,NN,.}","{2,5,4,2,0,8,8,5,0,11,8,14,14,11,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_96,"KRAS codon 61 mutation NOT identi?ed .","{KRAS,codon,61,mutation,NOT,identi?ed,.}","{KRAS,codon,61,mutation,not,identi?ed,.}","{NNP,NN,CD,NN,NN,VBN,.}","{6,5,5,5,1,0,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_97,"EGFR exon 18 mutation NOT identi?ed .","{EGFR,exon,18,mutation,NOT,identi?ed,.}","{egfr,exon,18,mutation,not,identi?ed,.}","{NN,NN,CD,NN,NN,VBN,.}","{2,6,5,5,2,0,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_98,".","{.}","{.}","{.}","{0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_99,"EGFR exon 19 mutation NOT identi?ed .","{EGFR,exon,19,mutation,NOT,identi?ed,.}","{egfr,exon,19,mutation,not,identi?ed,.}","{NN,NN,CD,NN,NN,VBN,.}","{2,6,5,5,2,0,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_100,"EGFR exon 20 mutation NOT identi?ed .","{EGFR,exon,20,mutation,NOT,identi?ed,.}","{egfr,exon,20,mutation,not,identi?ed,.}","{NN,NN,CD,NN,NN,VBN,.}","{2,6,5,5,2,0,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_101,"EGFR exon 21 mutation NOT identified .","{EGFR,exon,21,mutation,NOT,identified,.}","{egfr,exon,21,mutation,not,identify,.}","{NN,NN,CD,NN,RB,VBN,.}","{2,6,4,2,6,0,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_102,".","{.}","{.}","{.}","{0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_103,"BRAF codon 600 mutation NOT identi?ed .","{BRAF,codon,600,mutation,NOT,identi?ed,.}","{braf,codon,600,mutation,not,identi?ed,.}","{NN,NN,CD,NN,NN,VBN,.}","{2,6,5,5,2,0,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_104,"? - ' 3I "" "" ! "" ""","{?,-,',3I,""\"""",""\"""",!,""\"""",""\""""}","{?,-,',3us,""\"""",""\"""",!,""\"""",""\""""}","{SYM,:,'',NN,'',``,.,'',''}","{6,0,0,6,4,0,0,6,6}","{}"
TCGA-50-8459, TCGA-50-8459SENT_105,"~ U. ? F ' .","{~,U.,?,F,',.}","{~,U.,?,f,',.}","{NN,NNP,JJ,NN,'',.}","{4,4,4,0,0,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_106,">","{>}","{>}","{JJR}","{0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_107,"NOTE : The quantity and quality of isolated DNA was acceptable for testing .","{NOTE,:,The,quantity,and,quality,of,isolated,DNA,was,acceptable,for,testing,.}","{note,:,the,quantity,and,quality,of,isolate,dna,be,acceptable,for,testing,.}","{VB,:,DT,NN,CC,NN,IN,VBN,NN,VBD,JJ,IN,NN,.}","{0,0,4,11,0,4,0,9,4,11,1,0,11,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_108,"BACKGROUND : EGFR mutations are present in about 10-1 5 % of non-Asian and up to 40 % of the Asian patients with non-small-cell lung cancer ( NSCLC ) ( 1.2 ) .","{BACKGROUND,:,EGFR,mutations,are,present,in,about,10-1,5,%,of,non-Asian,and,up,to,40,%,of,the,Asian,patients,with,non-small-cell,lung,cancer,(,NSCLC,),(,1.2,),.}","{background,:,egfr,mutation,be,present,in,about,10-1,5,%,of,non-asian,and,up,to,40,%,of,the,asian,patient,with,non-small-cell,lung,cancer,(,nsclc,),(,1.2,),.}","{NN,:,NN,NNS,VBP,JJ,IN,IN,CD,CD,NN,IN,JJ,CC,RB,TO,CD,NN,IN,DT,JJ,NNS,IN,JJ,NN,NN,CD,NN,CD,CD,CD,NN,.}","{0,0,4,6,6,1,6,7,11,11,8,0,11,0,11,0,18,15,0,22,22,18,0,28,28,28,28,22,30,8,32,30,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_109,"They are more frequent in non-smokersrfemales , and in tumors with adenocarcinoma histology .","{They,are,more,frequent,in,non-smokersrfemales,"","",and,in,tumors,with,adenocarcinoma,histology,.}","{they,be,more,frequent,in,non-smokersrfemale,"","",and,in,tumor,with,adenocarcinoma,histology,.}","{PRP,VBP,RBR,JJ,IN,NNS,"","",CC,IN,NNS,IN,NN,NN,.}","{4,4,4,0,0,4,0,0,0,4,0,13,10,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_110,"Activating EGFR mutations including exon 19 deletions , exon 21 point mutations ( L858R .","{Activating,EGFR,mutations,including,exon,19,deletions,"","",exon,21,point,mutations,(,L858R,.}","{activate,egfr,mutation,include,exon,19,deletion,"","",exon,21,point,mutation,(,l858r,.}","{VBG,NN,NNS,VBG,NN,CD,NNS,"","",NN,CD,NN,NNS,VBP,NN,.}","{13,3,1,0,3,5,12,0,12,12,12,13,0,13,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_111,"L861Q ) .","{L861Q,),.}","{l861q,),.}","{NN,NN,.}","{0,1,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_112,"and exon 18 G719AlClS point mutation are associated with the clinical response to treatment with EGFR tyrosine kinase inhibitors ( TKI ) ( ge?tinib , erlotinib ) ( 2-4 ) .","{and,exon,18,G719AlClS,point,mutation,are,associated,with,the,clinical,response,to,treatment,with,EGFR,tyrosine,kinase,inhibitors,(,TKI,),(,ge?tinib,"","",erlotinib,),(,2-4,),.}","{and,exon,18,g719alcl,point,mutation,be,associate,with,the,clinical,response,to,treatment,with,egfr,tyrosine,kinase,inhibitor,(,tkus,),(,ge?tinib,"","",erlotinib,),(,2-4,),.}","{CC,NN,CD,NN,NN,NN,VBP,VBN,IN,DT,JJ,NN,TO,NN,IN,NN,NN,NN,NNS,VBP,NN,CD,NN,NN,"","",NN,CD,CD,CD,NN,.}","{20,20,6,6,6,8,8,2,0,12,12,8,0,8,0,19,19,19,8,0,24,24,24,20,0,24,28,26,30,28,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_113,"Advanced NSCLC patients with activating EGFR mutations show response rates of more than 70 % , with progression-free survival up to 14 month ( 2.3 ) .","{Advanced,NSCLC,patients,with,activating,EGFR,mutations,show,response,rates,of,more,than,70,%,"","",with,progression-free,survival,up,to,14,month,(,2.3,),.}","{Advanced,NSCLC,patient,with,activate,egfr,mutation,show,response,rate,of,more,than,70,%,"","",with,progression-free,survival,up,to,14,month,(,2.3,),.}","{NNP,NNP,NNS,IN,VBG,NN,NNS,VBP,NN,NNS,IN,JJR,IN,CD,NN,"","",IN,JJ,NN,IN,TO,CD,NN,CD,CD,NN,.}","{3,3,8,0,7,7,3,0,10,8,0,13,14,15,10,0,0,19,8,26,0,23,20,25,26,19,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_114,"However .","{However,.}","{however,.}","{RB,.}","{0,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_115,"EGFR mutations inexon 20 ( insertions and T790iili point mutation ) are associated with acquired resistance to TKis ( 4 ) .","{EGFR,mutations,inexon,20,(,insertions,and,T790iili,point,mutation,),are,associated,with,acquired,resistance,to,TKis,(,4,),.}","{egfr,mutation,inexon,20,(,insertion,and,t790iilus,point,mutation,),be,associate,with,acquire,resistance,to,TKis,(,4,),.}","{NN,NNS,VBP,CD,CD,NNS,CC,NN,NN,NN,NN,VBP,VBN,IN,VBN,NN,TO,NNP,CD,CD,NN,.}","{2,3,13,5,6,3,0,11,11,11,3,13,0,0,16,13,0,16,18,21,13,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_116,"KRAS mutations and BRAF mutations are found In approximately 30 % and 2 % of lung adenocarcinomas respectively .","{KRAS,mutations,and,BRAF,mutations,are,found,In,approximately,30,%,and,2,%,of,lung,adenocarcinomas,respectively,.}","{KRAS,mutation,and,braf,mutation,be,find,in,approximately,30,%,and,2,%,of,lung,adenocarcinoma,respectively,.}","{NNP,NNS,CC,NN,NNS,VBP,VBN,IN,RB,CD,NN,CC,CD,NN,IN,NN,NNS,RB,.}","{2,7,0,5,2,7,0,0,14,14,14,0,14,7,0,17,14,7,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_117,"The most common mutation types are KRAS codon ? i2l13 and BRAF VBOOE .","{The,most,common,mutation,types,are,KRAS,codon,?,i2l13,and,BRAF,VBOOE,.}","{the,most,common,mutation,type,be,KRAS,codon,?,i2l13,and,braf,vbooe,.}","{DT,RBS,JJ,NN,NNS,VBP,NNP,NN,CD,NN,CC,NN,NN,.}","{5,3,5,5,8,8,8,0,10,8,0,13,8,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_118,"Patients with these mutations tend to be resistant to eriotinib and ge?tinib ( 25.6 ) .","{Patients,with,these,mutations,tend,to,be,resistant,to,eriotinib,and,ge?tinib,(,25.6,),.}","{patient,with,these,mutation,tend,to,be,resistant,to,eriotinib,and,ge?tinib,(,25.6,),.}","{NNS,IN,DT,NNS,VBP,TO,VB,JJ,TO,NN,CC,NN,CD,CD,NN,.}","{5,0,4,1,0,8,8,5,0,8,0,10,14,15,12,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_119,"However , not all tumors reveal such a correlation and , therefore , the results of molecular testing should be interpreted in conjunction with other laboratory and clinical ?ndings .","{However,"","",not,all,tumors,reveal,such,a,correlation,and,"","",therefore,"","",the,results,of,molecular,testing,should,be,interpreted,in,conjunction,with,other,laboratory,and,clinical,?ndings,.}","{however,"","",not,all,tumor,reveal,such,a,correlation,and,"","",therefore,"","",the,result,of,molecular,testing,should,be,interpret,in,conjunction,with,other,laboratory,and,clinical,?ndings,.}","{RB,"","",RB,DT,NNS,VBP,JJ,DT,NN,CC,"","",RB,"","",DT,NNS,IN,JJ,NN,MD,VB,VBN,IN,NN,IN,JJ,NN,CC,JJ,NNS,.}","{6,0,5,5,6,0,6,9,7,6,0,21,0,15,21,0,18,15,21,21,6,0,21,0,26,21,0,29,26,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_120,"MUTATIONAL ANALYSIS : For cytology samples , extraction of DNA was performed from the ?uid or sample provided .","{MUTATIONAL,ANALYSIS,:,For,cytology,samples,"","",extraction,of,DNA,was,performed,from,the,?uid,or,sample,provided,.}","{mutational,analysis,:,for,cytology,sample,"","",extraction,of,dna,be,perform,from,the,?uid,or,sample,provide,.}","{JJ,NN,:,IN,NN,NNS,"","",NN,IN,NN,VBD,VBN,IN,DT,NN,CC,NN,VBN,.}","{2,0,0,0,6,12,0,12,0,8,12,2,0,15,12,0,15,15,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_121,"For surgical specimens , manual microclissectlon was performed .","{For,surgical,specimens,"","",manual,microclissectlon,was,performed,.}","{for,surgical,specimen,"","",manual,microclissectlon,be,perform,.}","{IN,JJ,NNS,"","",JJ,NN,VBD,VBN,.}","{0,3,8,0,6,8,8,0,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_122,"Specimens with the minimum of 50 % of tumor cells in a microdissection target or more than 300 cells for FNA specimen were accepted for the analysis .","{Specimens,with,the,minimum,of,50,%,of,tumor,cells,in,a,microdissection,target,or,more,than,300,cells,for,FNA,specimen,were,accepted,for,the,analysis,.}","{specimen,with,the,minimum,of,50,%,of,tumor,cell,in,a,microdissection,target,or,more,than,300,cell,for,FNA,specimen,be,accept,for,the,analysis,.}","{NNS,IN,DT,NN,IN,CD,NN,IN,NN,NNS,IN,DT,NN,NN,CC,JJR,IN,CD,NNS,IN,NNP,NN,VBD,VBN,IN,DT,NN,.}","{24,0,4,1,0,7,4,0,10,7,0,14,14,10,0,17,18,19,10,0,22,19,24,0,0,27,24,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_123,"DNA was isolated using standard laboratory procedure .","{DNA,was,isolated,using,standard,laboratory,procedure,.}","{dna,be,isolate,use,standard,laboratory,procedure,.}","{NN,VBD,VBN,VBG,JJ,NN,NN,.}","{3,3,0,3,7,7,4,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_124,"Optical density readings were obtained .","{Optical,density,readings,were,obtained,.}","{Optical,density,reading,be,obtain,.}","{NNP,NN,NNS,VBD,VBN,.}","{3,3,5,5,0,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_125,"For the detection of mutation , DNA was ampli?ed with primers for the exons 2 and 3 of the KRAS gene and axons 18-21 of the EGFR gene .","{For,the,detection,of,mutation,"","",DNA,was,ampli?ed,with,primers,for,the,exons,2,and,3,of,the,KRAS,gene,and,axons,18-21,of,the,EGFR,gene,.}","{for,the,detection,of,mutation,"","",dna,be,ampli?ed,with,primer,for,the,exon,2,and,3,of,the,KRAS,gene,and,axon,18-21,of,the,egfr,gene,.}","{IN,DT,NN,IN,NN,"","",NN,VBD,VBN,IN,NNS,IN,DT,NNS,CD,CC,CD,IN,DT,NNP,NN,CC,NNS,CD,IN,DT,NN,NN,.}","{0,3,9,0,3,0,9,9,0,0,9,0,14,11,11,0,11,0,21,21,15,0,11,23,0,28,28,23,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_126,"Then , fonvaro ? and reverse sequencing was performed using the BigDye Tenninator Kit on ABl3 ' l30 q The sequencing eleotropherograms were analyzed for the presence of mutations .","{Then,"","",fonvaro,?,and,reverse,sequencing,was,performed,using,the,BigDye,Tenninator,Kit,on,ABl3,',l30,q,The,sequencing,eleotropherograms,were,analyzed,for,the,presence,of,mutations,.}","{then,"","",fonvaro,?,and,reverse,sequencing,be,perform,use,the,BigDye,Tenninator,kit,on,abl3,',l30,q,the,sequencing,eleotropherogram,be,analyze,for,the,presence,of,mutation,.}","{RB,"","",NN,NN,CC,VB,NN,VBD,VBN,VBG,DT,NNP,NNP,NN,IN,NN,'',NN,VBD,DT,NN,NNS,VBD,VBN,IN,DT,NN,IN,NNS,.}","{19,0,4,19,0,15,9,9,6,9,14,14,14,10,19,18,0,15,0,22,22,24,24,19,0,27,24,0,27,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_127,"The method sensitivity is approximately 20 % of mutant a e es in a background of normal DNA .","{The,method,sensitivity,is,approximately,20,%,of,mutant,a,e,es,in,a,background,of,normal,DNA,.}","{the,method,sensitivity,be,approximately,20,%,of,mutant,a,e,e,in,a,background,of,normal,dna,.}","{DT,NN,NN,VBZ,RB,CD,NN,IN,NN,DT,SYM,NNS,IN,DT,NN,IN,JJ,NN,.}","{3,3,7,7,6,7,0,0,7,9,12,7,0,15,12,0,18,15,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_128,"For detection of BRAF mutation , real-time PCR was perfonned on the Lightcycler platform to amplify BRAF codons 599-601 sequences .","{For,detection,of,BRAF,mutation,"","",real-time,PCR,was,perfonned,on,the,Lightcycler,platform,to,amplify,BRAF,codons,599-601,sequences,.}","{for,detection,of,braf,mutation,"","",real-time,pcr,be,perfonn,on,the,Lightcycler,platform,to,amplify,braf,codon,599-601,sequence,.}","{IN,NN,IN,NN,NN,"","",JJ,NN,VBD,VBN,IN,DT,NNP,NN,TO,VB,NN,NNS,JJ,NNS,.}","{0,10,0,5,2,0,8,10,10,0,0,14,14,10,16,10,18,20,20,16,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_129,"Post-PCR melting curve analysis was used to detect possible mutations .","{Post-PCR,melting,curve,analysis,was,used,to,detect,possible,mutations,.}","{post-pcr,melting,curve,analysis,be,use,to,detect,possible,mutation,.}","{NN,NN,NN,NN,VBD,VBN,TO,VB,JJ,NNS,.}","{2,3,0,6,6,3,8,6,10,8,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_130,"if required , the mutation type was con?rmed by Sanger sequencing of the PCR product on ABl3130 .","{if,required,"","",the,mutation,type,was,con?rmed,by,Sanger,sequencing,of,the,PCR,product,on,ABl3130,.}","{if,require,"","",the,mutation,type,be,con?rmed,by,Sanger,sequencing,of,the,pcr,product,on,abl3130,.}","{IN,VBN,"","",DT,NN,NN,VBD,VBN,IN,NNP,NN,IN,DT,NN,NN,IN,NN,.}","{2,8,0,6,6,8,8,0,0,11,8,0,15,15,11,0,8,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_131,"The limit of detection is approximately 10-20 % of alleles with mutation present in the background of normal DNA .","{The,limit,of,detection,is,approximately,10-20,%,of,alleles,with,mutation,present,in,the,background,of,normal,DNA,.}","{the,limit,of,detection,be,approximately,10-20,%,of,allele,with,mutation,present,in,the,background,of,normal,dna,.}","{DT,NN,IN,NN,VBZ,RB,CD,NN,IN,NNS,IN,NN,JJ,IN,DT,NN,IN,JJ,NN,.}","{2,13,0,2,13,13,8,6,0,6,0,10,0,0,16,13,0,19,16,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_132,"in Situ Procedure Intergretation PROBE : LSI ALK Dual-Color Break-apart Probe 2p23","{in,Situ,Procedure,Intergretation,PROBE,:,LSI,ALK,Dual-Color,Break-apart,Probe,2p23}","{in,Situ,Procedure,Intergretation,PROBE,:,LSI,ALK,Dual-Color,Break-apart,Probe,2p23}","{IN,NNP,NNP,NNP,NNP,:,NNP,NNP,NNP,NNP,NNP,NN}","{5,3,1,5,0,0,12,12,12,12,12,5}","{}"
TCGA-50-8459, TCGA-50-8459SENT_133,"ALK FISH STUDIES PERFORMED on THE ADENOCARCINOMA ARE NEGATIVE .","{ALK,FISH,STUDIES,PERFORMED,on,THE,ADENOCARCINOMA,ARE,NEGATIVE,.}","{ALK,fish,study,perform,on,the,adenocarcinoma,be,negative,.}","{NNP,NN,NNS,VBN,IN,DT,NN,VBP,NN,.}","{3,3,9,3,0,7,4,9,0,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_134,"Number of cells analyzed : 61 % of cells positive for the ALK rearrangement : o %","{Number,of,cells,analyzed,:,61,%,of,cells,positive,for,the,ALK,rearrangement,:,o,%}","{number,of,cell,analyze,:,61,%,of,cell,positive,for,the,ALK,rearrangement,:,o,%}","{NN,IN,NNS,VBN,:,CD,NN,IN,NNS,JJ,IN,DT,NNP,NN,:,NN,NN}","{0,0,1,3,0,7,3,0,7,9,0,14,14,10,0,17,7}","{}"
TCGA-50-8459, TCGA-50-8459SENT_135,"Only split o & G ( single o and single G in the same nucleus : o % Fusion + split o and G In the same nucleus : o % Only single o : o % Fusion + single o : o %","{Only,split,o,&,G,(,single,o,and,single,G,in,the,same,nucleus,:,o,%,Fusion,+,split,o,and,G,In,the,same,nucleus,:,o,%,Only,single,o,:,o,%,Fusion,+,single,o,:,o,%}","{only,split,o,&,G,(,single,o,and,single,g,in,the,same,nucleus,:,o,%,fusion,+,split,o,and,g,in,the,same,nucleus,:,o,%,only,single,o,:,o,%,fusion,+,single,o,:,o,%}","{RB,NN,NN,CC,NNP,CD,JJ,NN,CC,JJ,NN,IN,DT,JJ,NN,:,NN,NN,NN,CC,NN,NN,CC,NN,IN,DT,JJ,NN,:,NN,NN,RB,JJ,NN,:,NN,NN,NN,CC,JJ,NN,:,NN,NN}","{3,3,0,0,3,5,8,3,0,11,3,0,15,15,8,0,19,19,8,0,22,19,0,19,0,28,28,22,0,31,8,34,34,31,0,38,38,8,0,41,8,0,8,43}","{}"
TCGA-50-8459, TCGA-50-8459SENT_136,"% of the cells with the normal pattem : 61 ( 10n % ) ALK FISH analysis was manually pertomted and quantitatively assessed by analysis of a minimum of 60 cells using the ALK SpectrumOrange ( telome?c ) and the ALK SpectrumGreen ( centrorneric ) probes .","{%,of,the,cells,with,the,normal,pattem,:,61,(,10n,%,),ALK,FISH,analysis,was,manually,pertomted,and,quantitatively,assessed,by,analysis,of,a,minimum,of,60,cells,using,the,ALK,SpectrumOrange,(,telome?c,),and,the,ALK,SpectrumGreen,(,centrorneric,),probes,.}","{%,of,the,cell,with,the,normal,pattem,:,61,(,10n,%,),ALK,fish,analysis,be,manually,pertomt,and,quantitatively,assess,by,analysis,of,a,minimum,of,60,cell,use,the,ALK,SpectrumOrange,(,telome?c,),and,the,ALK,SpectrumGreen,(,centrorneric,),probe,.}","{NN,IN,DT,NNS,IN,DT,JJ,NN,:,CD,CD,CD,NN,CD,NNP,NN,NN,VBD,RB,VBN,CC,RB,VBN,IN,NN,IN,DT,NN,IN,CD,NNS,VBG,DT,NNP,NNP,NN,NN,NN,CC,DT,NNP,NNP,NN,JJ,NN,NNS,.}","{23,0,4,1,0,8,8,4,0,11,1,13,11,17,17,17,1,20,20,0,0,23,20,0,23,0,28,25,0,31,28,23,38,38,38,38,38,32,0,43,43,43,32,46,46,20,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_137,"PROBE : c-MET ? / CEP7 _ ? Cytogenetlc Location : 7q31 .2 l7p11.1-q11 .1 C-MET FISH STUDIES PERFORMED ON THE ADENOCARCINOMA ARE NEGATIVE FOR AMPLIFICATION .","{PROBE,:,c-MET,?,/,CEP7,_,?,Cytogenetlc,Location,:,7q31,.2,l7p11.1-q11,.1,C-MET,FISH,STUDIES,PERFORMED,ON,THE,ADENOCARCINOMA,ARE,NEGATIVE,FOR,AMPLIFICATION,.}","{probe,:,c-met,?,/,cep7,_,?,Cytogenetlc,Location,:,7q31,.2,l7p11.1-q11,.1,C-MET,fish,study,perform,on,the,adenocarcinoma,be,negative,for,amplification,.}","{NN,:,NN,CD,:,CD,CD,CD,NNP,NNP,:,CD,NN,NN,CD,NNP,NN,NNS,VBD,IN,DT,NN,VBP,JJ,IN,NN,.}","{0,0,1,3,10,10,10,10,10,3,0,14,14,10,18,18,18,19,3,24,22,20,24,19,0,24,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_138,"Number of oells analyzed : 60 Ratio c-METICEP7 : 1.05","{Number,of,oells,analyzed,:,60,Ratio,c-METICEP7,:,1.05}","{number,of,oell,analyze,:,60,ratio,c-meticep7,:,1.05}","{NN,IN,NNS,VBN,:,CD,NN,NN,:,CD}","{0,0,1,3,0,8,8,3,0,8}","{}"
TCGA-50-8459, TCGA-50-8459SENT_139,"SNR ( signal to nucleus ratio ) : 1.9 CNR ( centromere to nucleus ratio ) : 1.8 Results ALK translocatlon is detected as follows :","{SNR,(,signal,to,nucleus,ratio,),:,1.9,CNR,(,centromere,to,nucleus,ratio,),:,1.8,Results,ALK,translocatlon,is,detected,as,follows,:}","{snr,(,signal,to,nucleus,ratio,),:,1.9,cnr,(,centromere,to,nucleus,ratio,),:,1.8,result,alk,translocatlon,be,detect,as,follow,:}","{NN,NN,NN,TO,NN,NN,CD,:,CD,NN,CD,NN,TO,NN,NN,CD,:,CD,NNS,NN,NN,VBZ,VBN,IN,VBZ,:}","{3,3,0,0,6,3,6,0,10,3,12,10,0,15,12,15,0,19,3,21,23,23,19,25,23,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_140,"ALK negative : 0-15 % of cells positive for the ALK rearrangement .","{ALK,negative,:,0-15,%,of,cells,positive,for,the,ALK,rearrangement,.}","{ALK,negative,:,0-15,%,of,cell,positive,for,the,ALK,rearrangement,.}","{NNP,JJ,:,CD,NN,IN,NNS,JJ,IN,DT,NNP,NN,.}","{2,0,0,5,8,0,5,2,0,12,12,8,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_141,"Normal cells without the ALK translocation show green and orange signals in juxtaposition .","{Normal,cells,without,the,ALK,translocation,show,green,and,orange,signals,in,juxtaposition,.}","{normal,cell,without,the,ALK,translocation,show,green,and,orange,signal,in,juxtaposition,.}","{JJ,NNS,IN,DT,NNP,NN,NN,JJ,CC,JJ,NNS,IN,NN,.}","{2,7,0,6,6,2,0,11,0,11,7,0,11,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_142,"ALK positive : Greater than 15 % of cells positive for the ALK rearrangement .","{ALK,positive,:,Greater,than,15,%,of,cells,positive,for,the,ALK,rearrangement,.}","{alk,positive,:,Greater,than,15,%,of,cell,positive,for,the,ALK,rearrangement,.}","{NN,JJ,:,NNP,IN,CD,NN,IN,NNS,JJ,IN,DT,NNP,NN,.}","{2,0,0,10,0,7,4,0,7,2,0,14,14,10,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_143,"Cells with the ALK translocalion show one of the following pattems : One pair of signals ( green and orange ) fused or inujuxtaposition and one green and one orange signal separated ; Only split o & G ( single o and single G in the same nucleus ) ; Only single o ; Fusion 1 - single o. '","{Cells,with,the,ALK,translocalion,show,one,of,the,following,pattems,:,One,pair,of,signals,(,green,and,orange,),fused,or,inujuxtaposition,and,one,green,and,one,orange,signal,separated,;,Only,split,o,&,G,(,single,o,and,single,G,in,the,same,nucleus,),;,Only,single,o,;,Fusion,1,-,single,o.,'}","{cell,with,the,alk,translocalion,show,one,of,the,follow,pattem,:,one,pair,of,signal,(,green,and,orange,),fuse,or,inujuxtaposition,and,one,green,and,one,orange,signal,separate,;,only,split,o,&,G,(,single,o,and,single,g,in,the,same,nucleus,),;,only,single,o,;,fusion,1,-,single,o.,'}","{NNS,IN,DT,NN,NN,VBP,CD,IN,DT,VBG,NNS,:,CD,NN,IN,NNS,CD,JJ,CC,JJ,NN,VBN,CC,NN,CC,CD,JJ,CC,CD,NN,NN,VBN,:,JJ,NN,NN,CC,NNP,CD,JJ,NN,CC,JJ,NN,IN,DT,JJ,NN,NN,:,RB,JJ,NN,:,NN,CD,:,JJ,NN,''}","{6,0,5,5,1,0,6,0,11,11,7,0,14,7,0,14,18,16,0,21,18,14,0,22,0,27,22,0,31,31,14,31,0,36,36,14,0,14,38,41,38,0,44,14,0,49,49,49,44,0,53,53,49,0,49,55,0,59,49,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_144,"c-MET ampli?cation is detected as follows :","{c-MET,ampli?cation,is,detected,as,follows,:}","{c-met,ampli?cation,be,detect,as,follow,:}","{NN,NN,VBZ,VBN,IN,VBZ,:}","{2,4,4,0,6,4,0}","{}"
TCGA-50-8459, TCGA-50-8459SENT_145,"c-ME T FISH positive : Gene Ampli?cation : Ratio genelchromosome more than two c-MET FISH negative : Ratio genelchromosome less than two","{c-ME,T,FISH,positive,:,Gene,Ampli?cation,:,Ratio,genelchromosome,more,than,two,c-MET,FISH,negative,:,Ratio,genelchromosome,less,than,two}","{c-me,t,fish,positive,:,Gene,Ampli?cation,:,ratio,genelchromosome,more,than,two,c-met,fish,negative,:,ratio,genelchromosome,less,than,two}","{NN,NN,NN,JJ,:,NNP,NNP,:,NN,NN,JJR,IN,CD,NN,NN,JJ,:,NN,NN,JJR,IN,CD}","{3,3,0,3,0,7,3,0,10,7,12,13,15,15,16,10,0,19,10,21,22,19}","{}"
